Bocca-Peralta G, Jiménez-León M, Iglesias-Bernal A, Calero-Chiriboga C

Language: Spanish
References: 13
Page: 12-14
PDF size: 150.09 Kb.

ABSTRACT

The prevalence of sialorrhea in children with cerebral palsy is high, presenting in up to 58% of the cases. This has an impact on the physical, psycho-social, and economic aspects of the patient and their family’s quality of life. The objective of this study was to evaluate the clinical efficacy of botulinum toxin type A in the management of sialorrhea in patients with cerebral palsy, as well to determine its effectiveness over time. Material and methods: This research was based on a cross-sectional, descriptive study of 15 pediatric patients aged 2-9 years with the diagnosis of cerebral palsy and sialorrhea. No control group was used, all participants received botulinum toxin type A 500 U in both, parotid and submaxillary glands, transcutaneously and under ultrasound guidance. The severity and frequency scale was used. Results: Improvement of the sialorrhea given by the measurement scale, with an average response duration of four months, and with a case of swallowing alteration, were evidenced. Conclusion: The use of botulinum toxin type A as a treatment for sialorrhea in pediatric patients with cerebral palsy is useful, effective and safe.

REFERENCES

1. Dias BL, Fernandes AR, Maia Filho HS. Sialorrhea in children with cerebral palsy. J Pediatr (Rio J). 2016; 92 (6): 549-558. doi: 10.1016/j.jped.2016.03.006.

2. Arellano-Saldaña M, Rodríguez-Silverio J, Morales-Osorio M, Arenas-Sordo ML. Eficacia clínica de la aplicación de toxina botulínica tipo A en las glándulas submaxilares para el tratamiento de la sialorrea profusa en pacientes pediátricos con parálisis cerebral. Investigación en Discapacidad. 2014; 3 (3): 101-105.

3. Cisneros-Lesser J, Hernández-Palestina M. Tratamiento del paciente con sialorrea. Revisión sistemática. Investigación en Discapacidad. 2017; 6 (1): 17-24.

4. Tahmassebi J, Curzon M. Prevalence of drooling in children with cerebral palsy attending special schools. Dev Med Child Neurol. 2003; 45: 613-617.

5. Sullivan PB, Lambert B, Rose M, Ford-Adams M, Johnson A, Griffiths P. Prevalence and severity of feeding and nutritional problems in children with neurological impairment: Oxford Feeding Study. Dev Med Child Neurol. 2000; 42 (10): 674-680.

6. de Mello SM, Alderete FS. Botulinum toxin A to sialorrhea treatment: a systematic review. Acta Fisiátrica. 2013; 20 (3): 147-151. doi: 10.5935/0104-7795.20130024.

7. Fuster TM, Berini AL, Gay EC. Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal. 2007; 12 (7): E511-516.

8. Aguilar-Rebolledo F. Espasticidad y toxina botulínica. Cap. 27, Ed. DEMSA, México 2008, pp. 361-363.

9. Ramió ME, Mas CA, Vinent GJ, Farré RR. Toxina botulínica: evidencia de uso en pediatría. An Pediatr Contin. 2012; 10 (2): 101-104.

10. Narbona J, Concejo C. Tratamiento de la incontinencia salival en el niño con patología neurológica. Acta Pediatr Esp. 2007; 65 (2): 56-60.

11. Alvarado-Gutiérrez AY, Hernández-Franco J, Sánchez-Villavicencio I. Toxina botulínica tipo A en el tratamiento de sialorrea en pacientes con enfermedad de Parkinson. Arch Neurocien. 2015; 20 (3): 174-181.

12. Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC. Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double blind, placebo-controlled study. J Child Neurol. 2011; 26 (7): 838-843.

13. Pérez GI, Jiménez FL, Otálora A. Toxina botulínica aplicada bajo guía ecográfica en el tratamiento de la sialorrea: reporte de dos casos. Univ Med. 2016; 57 (2): 264-272. doi: 10.11144/Javeriana.umed57-2.tba.